Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

M7824

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

- PMLiVE

Merck makes $17bn play for Sigma-Aldrich

Hopes their biggest deal to date will increase exposure to Asian markets

Merck KGaA shakes up pharma leadership

Stefan Oschmann becomes deputy CEO as Belén Garijo assumes more responsibility

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

- PMLiVE

J&J’s Imbruvica wins new cancer indication

FDA backs drug’s use in chronic lymphocytic leukaemia patients with genetic mutation

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Merck Serono to offer innovation grants

Will provide funding of €20m for research and med ed projects

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Merck KGaA furthers antibody ambitions in cancer

Signs deal with Mersana to develop antibody-drug conjugates

- PMLiVE

Merck KGaA drops Ono-partnered multiple sclerosis drug

Decides phase III candidate ceralifimod isn't worth its continued investment

Roche - Basel

Roche and Merck boost manufacturing capacity

Pharma companies invest in European facilities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links